Key result
Personalized obstetric care and planning the timing of delivery and treatment initiation may improve outcomes for newborns with genetically diagnosed spinal muscular atrophy.
Why the study?
High-quality pregnancy and postnatal care are important for optimal outcomes with earlier treatment, leading investigators to examine obstetric and postnatal factors modifying clinical outcomes of mother-baby dyads with SMA.
Does gestational age at birth modify clinical outcomes and motor function in neonates with spinal muscular atrophy?
Observational
Does gestational age at birth modify clinical outcomes and motor function in neonates with spinal muscular atrophy?
Personalized obstetric care and planned delivery timing may improve outcomes for newborns with genetically diagnosed SMA by facilitating early treatment.
Higher gestational age linked to earlier SMA signs in 2-SMN2 neonates; hypothesis-generating for obstetric timing, needs prospective validation.
BACKGROUND AND OBJECTIVES: Enhanced efficacy with spinal muscular atrophy (SMA) treatments is demonstrated with earlier initiation, ideally before the onset of symptoms. High-quality pregnancy and postnatal care for mother-baby dyads with SMA are important to ensure optimal outcomes. The aim of this study was to investigate obstetric and postnatal factors that could modify clinical outcomes of mother-baby dyads with SMA. METHODS: copies, regression models examined differences in gestational age at birth with study outcomes at diagnostic assessment, including clinical manifestations of SMA, motor function scores assessed with the CHOP-INTEND scale, and compound muscle action potential (CMAP). RESULTS: copies. DISCUSSION: Early detection and timely administration of treatments are imperative in managing the rapid and severe loss of motor function that can occur in neonates with SMA. A personalized obstetric health care approach, prenatal testing, and planning the timing of delivery and initiation of treatment for newborns with genetically diagnosed SMA may improve outcomes.
No takes yet. Share an insight, caveat, or question.
Farrar et al. (2025) conducted an observational in Spinal Muscular Atrophy. Gestational age at birth was evaluated on Clinical manifestations of SMA, motor function scores (CHOP-INTEND), and compound muscle action potential (CMAP). Personalized obstetric care and planning the timing of delivery and treatment initiation may improve outcomes for newborns with genetically diagnosed spinal muscular atrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: